Prevention of inflammatory and metabolic complications in metabolically healthy overweight and obese subjects Nutritional, Metabolic, Endocrine
Conditions
Interventions
Volunteers willing to participate and practice intermittent fasting for four consecutive weeks from dawn to sunset were recruited. Body weight, height, and body measurements, blood samples and food in
Sponsors
University of Sharjah
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Metabolically healthy male or female adult subject (>18 years) 2. Overweight/obesity (BMI>25 kg/m²) 3. Willing to fast for consecutive four weeks from dawn to sunset, and willing to participate and sign the informed consent
Exclusion criteria
Exclusion criteria: 1. History of metabolic syndrome, diabetes, or cardiovascular disease 2. Taking regular medications or supplements 3. Following a weight-reducing diet 4. History of bariatric surgery within the last 6-9 months before commencing intermittent fasting 5. Pregnant or peri-menopausal woman
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measured using blood test: 1. Haptoglobin gene polymorphism genotype (fixed outcome), serum CD136, and serum haptoglobin were determined at baseline 2. Serum CD136, and serum haptoglobin levels were measured after four-week consecutive intermittent fasting | — |
Secondary
| Measure | Time frame |
|---|---|
| Measured at baseline, and after four weeks intermittent fasting: 1. Body weight (kg), BMI (kg/m²) 2. Inflammatory (IL-6, TNF-alpha, IL-10) and metabolic markers (lipid profile, glucose homeostasis) measured using blood test | — |
Countries
United Arab Emirates
Outcome results
None listed